| . | . | . | Univariate analysis . | Adjusted analysis . | ||
|---|---|---|---|---|---|---|
| . | Baseline . | After CPT . | Group β (P-value) . | Exposure β (P-value) . | β (P-value) . | Group × exposure β (P-value) . |
| PRA (ng/mL/h) | ||||||
| NT | 0.40 (0.17–0.80) | 0.58 (0.17–1.06) | –0.128 (P = .627) | 0.134 (P = .096) | Group: –0.088 (P = .750) | No interaction |
| HT | 0.27 (0.14–0.65) | 0.33 (0.15–0.94) | Exposure: 0.170 (P = .116) | –0.081 (P = .617) | ||
| PAC (pg/mL) | ||||||
| NT | 95.0 (66.3–151.0) | 83.0 (65.7–16.5) | –0.123 (P = .451) | –0.019 (P = .359) | Group: –0.130 (P = .431) | No interaction |
| HT | 80.4 (62.9–103.2) | 78.1 (60.5–115.0) | Exposure: –0.025 (P = .372) | 0.013 (P = .751) | ||
| . | . | . | Univariate analysis . | Adjusted analysis . | ||
|---|---|---|---|---|---|---|
| . | Baseline . | After CPT . | Group β (P-value) . | Exposure β (P-value) . | β (P-value) . | Group × exposure β (P-value) . |
| PRA (ng/mL/h) | ||||||
| NT | 0.40 (0.17–0.80) | 0.58 (0.17–1.06) | –0.128 (P = .627) | 0.134 (P = .096) | Group: –0.088 (P = .750) | No interaction |
| HT | 0.27 (0.14–0.65) | 0.33 (0.15–0.94) | Exposure: 0.170 (P = .116) | –0.081 (P = .617) | ||
| PAC (pg/mL) | ||||||
| NT | 95.0 (66.3–151.0) | 83.0 (65.7–16.5) | –0.123 (P = .451) | –0.019 (P = .359) | Group: –0.130 (P = .431) | No interaction |
| HT | 80.4 (62.9–103.2) | 78.1 (60.5–115.0) | Exposure: –0.025 (P = .372) | 0.013 (P = .751) | ||
Data are presented as median (interquartile range).
| . | . | . | Univariate analysis . | Adjusted analysis . | ||
|---|---|---|---|---|---|---|
| . | Baseline . | After CPT . | Group β (P-value) . | Exposure β (P-value) . | β (P-value) . | Group × exposure β (P-value) . |
| PRA (ng/mL/h) | ||||||
| NT | 0.40 (0.17–0.80) | 0.58 (0.17–1.06) | –0.128 (P = .627) | 0.134 (P = .096) | Group: –0.088 (P = .750) | No interaction |
| HT | 0.27 (0.14–0.65) | 0.33 (0.15–0.94) | Exposure: 0.170 (P = .116) | –0.081 (P = .617) | ||
| PAC (pg/mL) | ||||||
| NT | 95.0 (66.3–151.0) | 83.0 (65.7–16.5) | –0.123 (P = .451) | –0.019 (P = .359) | Group: –0.130 (P = .431) | No interaction |
| HT | 80.4 (62.9–103.2) | 78.1 (60.5–115.0) | Exposure: –0.025 (P = .372) | 0.013 (P = .751) | ||
| . | . | . | Univariate analysis . | Adjusted analysis . | ||
|---|---|---|---|---|---|---|
| . | Baseline . | After CPT . | Group β (P-value) . | Exposure β (P-value) . | β (P-value) . | Group × exposure β (P-value) . |
| PRA (ng/mL/h) | ||||||
| NT | 0.40 (0.17–0.80) | 0.58 (0.17–1.06) | –0.128 (P = .627) | 0.134 (P = .096) | Group: –0.088 (P = .750) | No interaction |
| HT | 0.27 (0.14–0.65) | 0.33 (0.15–0.94) | Exposure: 0.170 (P = .116) | –0.081 (P = .617) | ||
| PAC (pg/mL) | ||||||
| NT | 95.0 (66.3–151.0) | 83.0 (65.7–16.5) | –0.123 (P = .451) | –0.019 (P = .359) | Group: –0.130 (P = .431) | No interaction |
| HT | 80.4 (62.9–103.2) | 78.1 (60.5–115.0) | Exposure: –0.025 (P = .372) | 0.013 (P = .751) | ||
Data are presented as median (interquartile range).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
